(Q41274481)

29 September 2017

1 reference

title

Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate (English)

1 reference

29 September 2017

1 reference

1 reference

coronary artery disease

1 reference

Weintraub WS

1

1 reference

29 September 2017

Wenger NK

series ordinal

2

1 reference

29 September 2017

Parthasarathy S

series ordinal

3

1 reference

29 September 2017

Brown WV

series ordinal

4

1 reference

29 September 2017

publication date

1 December 1996

1 reference

Journal of Clinical Epidemiology

29 September 2017

published in

1 reference

29 September 2017

volume

49

1 reference

29 September 2017

issue

12

1 reference

29 September 2017

page(s)

1353-1358

1 reference

Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Prognostic significance of progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Might treatment of hypercholesterolaemia increase non-cardiac mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Health policy on blood cholesterol. Time to change directions

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Iron and the sex difference in heart disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

The iron paradigm of ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Stored iron and ischemic heart disease. Empirical support for a new paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Dietary iron intake and risk of coronary disease among men

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Body iron stores and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Reduced mortality associated with long-term postmenopausal estrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

Lipids and cardiovascular disease: Do the findings and therapy apply equally to men and women?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2896%2900270-3

7 January 2021

10.1016/S0895-4356(96)00270-3

Identifiers

DOI

1 reference

29 September 2017

1 reference